Intra-Cellular Therapies Initiates Phase I Clinical Program For Schizophrenia And Sleep Maintenance Disorders

"We be elated ITI-007 and ITI-722 are heartbreaking readdress into clinical study. These programs encircle a fresh assortment of pharmacologic chattels, that have the eventual to label the planned of antipsychotic medication analysis and attention of catnap maintain wildness," stated Sharon Mates, Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies. "We feel this logic may have of serious magnitude treatment advantages completed at the moment market drugs and also should be unconstrained of masses annoying by the side effects associated beside common therapy." About ITI-007 ITI-007 be an stridently reachable multiple which combine potent 5HT2A receptor antagonism with cell-type-specific modulation of phosphoprotein pathway downstream of dopamine receptors. As a dopamine receptor phosphoprotein modulator (DPPM), ITI-007 have double properties; it act by means of a post-synaptic antagonist and as a pre-synaptic partial agonist. The combination of ITI-007's high-potency barrier of 5HT2A receptors and falling short dopamine receptor whine will manufacture it would-be contained by sponsorship of the original commonness, to select a clinical dose able of drench 5HT2A receptors while documents the "dialing in" of an optimal amount of dopamine receptor modulation. The cleverness to optimize the even of dopamine receptor modulation hold give your declaration an oath for the moderation of psychotic symptom short incur glorious level of dopamine antagonism that raison d`etre motor disturbances and other deleterious side effects. In enhance, the wide-ranging demarcation of affinity at 5HT2A and D2 receptors may allow for rule of the decorous amount of dopamine modulation for antipsychotic maintenance therapy and the treatment of bipolar disorders.

ITI's technology frame CNSProfile(TM) has revealed ITI-007 is a novel phosphoprotein modulator, selectively blocking overactive dopamine at risk phosphoprotein pathways without put on ice compensatory dopamine league, demonstrating ITI-007's unique, partial agonist-like properties. Standard pharmacologic assay have confirmed ITI-007's partial agonist properties at the presynaptic dopamine D2 receptor and confirmed serotonin carrier antagonist activity which may be of added ability to patients with schizoaffective disorder and other disease associated with theme alterations. ITI-007 has a substantially belittle bent than several currently marketed antipsychotic drugs to fasten receptors that mediate deleterious cardiovascular dealings, sedation and speedy and significant freight gain.